Haemonetics Corp. (HAE) Misses Q2 EPS Views; Affirms Outlook
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $108.52 --0%
EPS Growth %: +1.6%
Financial Fact:
Total operating expenses: 79.45M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: +1.6%
Financial Fact:
Total operating expenses: 79.45M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Haemonetics Corp. (NYSE: HAE) reported Q2 EPS of $0.65, $0.13 worse than the analyst estimate of $0.78. Revenue for the quarter came in at $170.6 million versus the consensus estimate of $170.4 million.
Affirms outlook.
Affirms outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
- AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c
- Haemonetics (HAE) spreader of 500 contracts of November 115 and 130 calls as share price up 2.5%
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
